Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
Investigational New Drugs · 2023
DOI: 10.1007/s10637-023-01367-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational New Drugs, 2023. Verfasst von Li Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Hematologic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Key Project of Science and Technology Plan of Beijing Municipal Education Commission (Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
T cells are important components in the cell-mediated antitumour response. In recent years, bispecific antibodies (Bi-Abs) have become promising treatments because of their ability to recruit T cells that kill tumours. Here, we demonstrate that CD155 is expressed in a wide range of human haematologic tumours and report on the ability of the bispecific antibody anti-CD3 x anti-CD155 (CD155Bi-Ab) to activate T cells targeting malignant haematologic cells. The specific cytolytic effect of T cells armed with CD155Bi-Ab was evaluated by quantitative luciferase assay, and the results showed that the cytolytic effect of these cells was accompanied by an increase in the level of the cell-killing mediator perforin. Moreover, compared with their unarmed T-cell counterparts, CD155Bi-Ab-armed T cells induced significant cytotoxicity in CD155-positive haematologic tumour cells, as indicated by lactate dehydrogenase assays, and these results were accompanied by increased granzyme B secretion. Furthermore, CD155Bi-Ab-armed T cells produced more T-cell-derived cytokines, including TNF-α, IFN-γ, and IL-2. In conclusion, CD155Bi-Ab enhances the ability of T cells to kill haematologic tumour cells, and therefore, CD155 may serve as a novel target for immunotherapy against haematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
- Department of Gynecology and Obstetrics, China-Japan Friendship Hospital, Capital Medical University, Beijing, 100029, China.
- Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
- Department of Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
- College of Basic Medical Science, Peking University Health Science Center, Beijing, 100191, China.
- Department of Pathology, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China. liuhonggang@ccmu.edu.cn.
Förderung
- Key Project of Science and Technology Plan of Beijing Municipal Education Commission (Beijing Municipal Science and Technology Commission
Zitieren
APA
Ma, L., Ma, J., Sun, X., & Liu, H. (2023). Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies. Investigational New Drugs. https://doi.org/10.1007/s10637-023-01367-2
Vancouver
Ma L, Ma J, Sun X, Liu H. Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies. Investigational New Drugs. 2023. doi:10.1007/s10637-023-01367-2
BibTeX
@article{Ma2023,
author = {Ma, Li and Ma, Juan and Sun, Xin and Liu, Honggang},
title = {Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies},
journal = {Investigational New Drugs},
year = {2023},
doi = {10.1007/s10637-023-01367-2}
}
EUVIMED